WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H319922
CAS#: 208848-19-5
Description: Freselestat, also known as ONO-6818, is a potent neutrophil elastase inhibitor. Freselestat reduces inflammatory mediators during simulated extracorporeal circulation. ONO-6818 significantly reduced interleukin 8 and C5b-9 production. ONO-6818 did not modulate changes of CD11b and L-selectin during recirculation.
Hodoodo Cat#: H319922
Name: Freselestat
CAS#: 208848-19-5
Chemical Formula: C23H28N6O4
Exact Mass: 452.22
Molecular Weight: 452.515
Elemental Analysis: C, 61.05; H, 6.24; N, 18.57; O, 14.14
Synonym: ONO-6818; ONO6818; ONO 6818; ONO-PO 736; Freselestat
IUPAC/Chemical Name: 2-(5-amino-6-oxo-2-phenylpyrimidin-1(6H)-yl)-N-(1-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)-3-methyl-1-oxobutan-2-yl)acetamide
InChi Key: YSIHYROEMJSOAS-UHFFFAOYSA-N
InChi Code: InChI=1S/C23H28N6O4/c1-13(2)17(18(31)20-27-28-22(33-20)23(3,4)5)26-16(30)12-29-19(14-9-7-6-8-10-14)25-11-15(24)21(29)32/h6-11,13,17H,12,24H2,1-5H3,(H,26,30)
SMILES Code: O=C(NC(C(C1=NN=C(C(C)(C)C)O1)=O)C(C)C)CN(C(C2=CC=CC=C2)=NC=C3N)C3=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 452.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Stevens T, Ekholm K, Gränse M, Lindahl M, Kozma V, Jungar C, Ottosson T, Falk-Håkansson H, Churg A, Wright JL, Lal H, Sanfridson A. AZD9668: pharmacological characterization of a novel oral inhibitor of neutrophil elastase. J Pharmacol Exp Ther. 2011 Oct;339(1):313-20. doi: 10.1124/jpet.111.182139. Epub 2011 Jul 26. PubMed PMID: 21791628.
2: Hirota Y, Suzuki M, Yamaguchi K, Fujita T, Katsube N. Pathophysiological studies of trinitrobenzene sulfonic acid-induced colitis in Syrian hamsters (Mesocricetus auratus). Comp Med. 2005 Feb;55(1):45-54. PubMed PMID: 15766209.
3: Hirota Y, Suzuki M, Yamaguchi K, Fujita T, Katsube N. Effects of the neutrophil elastase inhibitor (ONO-6818) on acetic acid induced colitis in Syrian hamsters. J Vet Med Sci. 2004 Oct;66(10):1223-8. PubMed PMID: 15528853.
4: Yoshimura Y, Hiramatsu Y, Sato Y, Homma S, Enomoto Y, Jikuya T, Sakakibara Y. ONO-6818, a novel, potent neutrophil elastase inhibitor, reduces inflammatory mediators during simulated extracorporeal circulation. Ann Thorac Surg. 2003 Oct;76(4):1234-9. PubMed PMID: 14530017.
5: Donnelly LE, Rogers DF. Therapy for chronic obstructive pulmonary disease in the 21st century. Drugs. 2003;63(19):1973-98. Review. PubMed PMID: 12962514.
6: Trifilieff A. ONO-6818 Cortech/Ono. Curr Opin Investig Drugs. 2002 Aug;3(8):1161-4. Review. PubMed PMID: 12211408.
7: Kuraki T, Ishibashi M, Takayama M, Shiraishi M, Yoshida M. A novel oral neutrophil elastase inhibitor (ONO-6818) inhibits human neutrophil elastase-induced emphysema in rats. Am J Respir Crit Care Med. 2002 Aug 15;166(4):496-500. PubMed PMID: 12186827.
8: Ohbayashi H. Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80. Review. PubMed PMID: 12084007.
9: Terui T, Sano K, Okada M, Shirota H, Honda M, Ozawa M, Hirasawa N, Tamura G, Tagami H. Production and pharmacologic modulation of the granulocyte-associated allergic responses to ovalbumin in murine skin models induced by injecting ovalbumin-specific Th1 or Th2 cells. J Invest Dermatol. 2001 Aug;117(2):236-43. PubMed PMID: 11511299.
10: Ohmoto K, Okuma M, Yamamoto T, Kijima H, Sekioka T, Kitagawa K, Yamamoto S, Tanaka K, Kawabata K, Sakata A, Imawaka H, Nakai H, Toda M. Design and synthesis of new orally active inhibitors of human neutrophil elastase. Bioorg Med Chem. 2001 May;9(5):1307-23. PubMed PMID: 11377188.
11: Odagaki Y, Ohmoto K, Matsuoka S, Hamanaka N, Nakai H, Toda M, Katsuya Y. The crystal structure of the complex of non-peptidic inhibitor of human neutrophil elastase ONO-6818 and porcine pancreatic elastase. Bioorg Med Chem. 2001 Mar;9(3):647-51. PubMed PMID: 11310599.
12: Ohmoto K, Yamamoto T, Horiuchi T, Imanishi H, Odagaki Y, Kawabata K, Sekioka T, Hirota Y, Matsuoka S, Nakai H, Toda M, Cheronis JC, Spruce LW, Gyorkos A, Wieczorek M. Design and synthesis of new orally active nonpeptidic inhibitors of human neutrophil elastase. J Med Chem. 2000 Dec 28;43(26):4927-9. PubMed PMID: 11150162.
